louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04326647: Short-term Effects Kinesiotaping (KT) on Balance and Gait in Parkinson's Disease (DP)
Official title: Short-term Effects Kinesiotaping (KT) on Balance and Gait in Parkinson's Disease (DP)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Parkinson Disease
Kinesiotaping
Lead sponsor: University of Castilla-La Mancha
Sponsor class: OTHER
First posted: 2020-03-30
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To analyze the short-term effect of kinesiotaping in balance and gait on Parkinson's disease


Eligibility criteria: Inclusion Criteria:

* Diagnosis of stage III PD, according to the Hoehn and Yahr scale.
* Subjects who are in the age range of 50 to 80 years.
* Acceptance of informed consent.
* Not present a musculoskeletal disorder or other neurological disease that interferes with balance and / or walking.
* Not having a diagnosed vestibular disorder.

Exclusion Criteria:

* Diagnosis of parkinsonism o Parkison-Like.
* Taking medications that may interfere with the different variables evaluated.
* Allergy to any component of the bandage.
* Being a pacemaker.

Primary outcomes:
measure: Berg Test - T0
timeFrame: up to week
measure: Berg Test - T1
timeFrame: up to week
measure: Berg Test - T2
timeFrame: up to week
measure: Tinetti Gait Test - T0
timeFrame: up to week
measure: Tinetti Gait Test - T1
timeFrame: up to week
measure: Tinetti Gait Test - T2
timeFrame: up to week
measure: Up & Go Test - T0
timeFrame: up to week
measure: Up & Go Test - T1
timeFrame: up to week
measure: Up & Go Test - T2
timeFrame: up to week
measure: Parkinson's Disease Questionnaire - T0
timeFrame: up to month
measure: Parkinson's Disease Questionnaire - T1
timeFrame: up to month
measure: surface electromyography -T0
timeFrame: up to week
measure: surface electromyography -T1
timeFrame: up to week
measure: surface electromyography -T2
timeFrame: up to week
Secondary outcomes:
Other outcomes:
Locations:
city: Toledo
country: Spain
facility: Javier Merino Andrés
Study officials:
References:
Clinical trial NCT02312947: Coblation Versus Cold Adenoidectomy -Safety and Efficiency
Official title: Coblation Versus Cold Adenoidectomy -Safety and Efficiency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sleep Apnea, Obstructive
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2014-12-09
Enrollment: 60
Sex: ALL
Minimum age (years): 12
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Comparative two methods of adenoidectomy means the coblation adenoidectomy with the cold dissection adenoidectomy specifically inquire which method is safer and more efficient.

Detailed description: Obstructive sleep apnea(osa) in children is a very bother and frequent problem with clinical and behavioral impacts. The hypertrophied adenoid tissue obstructs the air way in the nasopharynx that initiates the common symptoms. The treatment from that concerning problems is in the operation rooms by diversity surgical methods, the very older one is the cold dissection adenoidectomy.

Recently many surgeons use the coblation system as a preferred method for adenoidectomy. This method was proof as a safe and efficient especially referring to the bleeding and the dehydration risk .

Many children that operated by the cold dissection forced to perform another one or two operations presumably due to the adenoid tissue that did not removed completely from the first operation .

our hypothesis is that the coblation systemis a safe and eficient method for adenoidectomy.

The aims of this project is to verify if our theory is corect by blinded comparision between two methods.

Eligibility criteria: Inclusion Criteria:

* children with obstructive symptoms
* the children must perform nasopharyngoscopy with clear evidence of obstructive symptoms ( video or polysomnography more than 5 RDI)

Exclusion Criteria:

* without any recent upper respiratory tract infection or clinical suspicious of adenoiditis.
* tonsillectomy
* Non randomalization, not blinded

Primary outcomes:
measure: safety (bleeding , dehydration or any other complications)
timeFrame: percent of bleeding and dehydration
Secondary outcomes:
measure: efficacy (pain post operation by scales evaluation)
timeFrame: pain and examination for residual adenoid tissue
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05235347: Sotrovimab Expanded Access Treatment Protocol (COVID-19)
Official title: Sotrovimab Expanded Access Treatment Protocol
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Covid19
Keywords: SARS-CoV-2
coronavirus
coronavirus disease 2019
COVID-19
Lead sponsor: Vir Biotechnology, Inc.
Sponsor class: INDUSTRY
First posted: 2022-02-11
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.


Eligibility criteria: Inclusion Criteria:

* In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab

OR

* patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria

Exclusion Criteria:

* Hospitalized due to COVID-19 (excludes nosocomial infection)
* Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Site
state: California
city: Boston
country: United States
facility: Site
state: Massachusetts
city: Saint Louis
country: United States
facility: Site
state: Missouri
city: Seattle
country: United States
facility: Site
state: Washington
Study officials:
References:
Clinical trial NCT04789447: Initial CT Findings and CO-RADS Stage in COVID-19
Official title: Comparison of Initial CT Findings and CO-RADS Stage in COVID-19 Patients With PCR, Inflammation and Coagulation Parameters in Diagnostic and Prognostic Perspectives
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
SARS-CoV Infection
Pneumonia, Viral
Keywords: COVID-19
SARS-CoV2 RT-PCR Testing
Thorax
Computerized Tomography
Mortality
Prognosis
Lead sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Sponsor class: OTHER
First posted: 2021-03-09
Enrollment: 895
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are diagnosed with Covid-19 in a two tertier hospital in Turkey

Brief summary: This study aims to determine whether patients with different real-time reverse transcriptase-polymerase chain reaction (PCR), chest computed tomography (CT) and laboratory findings have different clinical outcomes.

Detailed description: This study aims to determine the rates of PCR positivity and CT findings in hospitalized patients with a diagnosis of COVID-19, to determine whether there is a difference in mortality and need for ICU between patients grouped according to the PCR positivity and presence of CT findings, and to evaluate the effect of the CO-RADS stage on these outcomes. Moreover, it is to compare the effects of inflammation and coagulation markers and CO-RADS stage on the severity of the disease

Eligibility criteria: Inclusion Criteria:

* Aged 18 years and over,
* Having SARS-CoV-2 RT-PCR test and chest CT examinations performed at the time of application or within 24 hours after admission
* RT-PCR positivity in nasopharyngeal swabs sample, and/or the presence of clinical and laboratory findings of SARS-CoV-2 infection and/or the presence of COVID-19-compatible radiological findings in chest CT, and being diagnosed with COVID-19

Exclusion Criteria:

* Patients with negative SARS-CoV-2 PCR test, pneumonia on CT but not given Covid-19 treatment by not considering Covid-19 by their doctor will not be included.
* Patients whose data are not available
* Patients with poor CT image quality
* Patients who were transferred to another hospital

Primary outcomes:
measure: mortality
timeFrame: up to 30 days
Secondary outcomes:
measure: need for intensive care
timeFrame: up to 30 days
measure: need for intenvasive mechanical ventilation
timeFrame: up to 30 days
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Sultan Abdülhamid Han Training and Research Hospital
city: Istanbul
country: Turkey
facility: Sultan Abdülhamid Han Training and Research Hospital
Study officials:
affiliation: Sultan Abdülhamid Han Training and Rsearch Hospital
name: Elif Yıldırım Ayaz, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04122547: Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis
Official title: Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis: a Randomized Double-blind Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Exacerbation Copd
Bronchiectasis
Lung Function Decreased
Keywords: Bronchiectasis
roflumilast
exacerbation
lung function
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2019-10-10
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Roflumilast compare with placebo for decrease infected exacerbation in non-cystic Bronchiectasis

Detailed description: Efficacy and RCT compare roflumilast vs placebo for 6 months in frequent infectious exacerbation in non-cystic bronchiectasis in Thailand

Eligibility criteria: Inclusion Criteria:

* symptomatic Bronchiectasis
* history at least 2 exacerbation last year

Exclusion Criteria:

* comorbidity with chronic obstructive pulmonary disease

Primary outcomes:
measure: acute deterioration of of bronchiectasis symptoms
timeFrame: 6 months
Secondary outcomes:
measure: Lung functions
timeFrame: 6 months
measure: Exercise capacity
timeFrame: 6 months
Other outcomes:
measure: Health related Quality of life
timeFrame: 6 months
Locations:
city: Songkhla
country: Thailand
facility: Songklanagarind hospital
Study officials:
affiliation: Prince of Songkla University
name: Kanung Saejiam, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT00444847: Effect of Repeated Exposures to Compressed Air on Patients With AIDS
Official title: Effect of Repeated Exposure to Compressed Air on Patients With AIDS (Acquired Immunodeficiency Syndrome)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: AIDS
Keywords: AIDS
HIV
Hyperbaric Chamber
treatment experienced
Lead sponsor: Designed Altobaric Technology, Incorporated
Sponsor class: OTHER
First posted: 2007-03-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The exposure of human beings to markedly altered environments (ambient pressure and inhaled gas mixtures) has profound effects on their innate immune capacity to effectively combat viral illnesses. This Phase IIA clinical trial examines the effects of an exposure to a 4 atmospheric environment has on HIV-infected humans whose clinical condition has progressed to formal AIDS status.


Eligibility criteria: Inclusion Criteria:

* CD4 count \<200
* Viral load \> 5000

Exclusion Criteria:

* Opportunistic infection
* Concurrent neoplasm (see protocol)
* Immunomodulators
* HIV vaccination
* Investigational HIV drugs (see protocol)
* Pregnant women
* Major organ transplant

Primary outcomes:
measure: 1 - Safety
measure: 2 - Viral Load measure (blood and intracellular)
measure: 3 - CD4/CD8 levels
Secondary outcomes:
measure: ADL measurements
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Detroit Receiving Hospital
state: Michigan
Study officials:
affiliation: Designed Altobaric Environment Technology
name: Stephen D. Guthrie, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Designed Altobaric Environment Technology
name: Stephen G Guthrie, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00434447: Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Official title: A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Bone Neoplasms
Keywords: Prostate Cancer
Breast Cancer
Multiple Myeloma
Zoledronic acid
Bone metastases
Skeletal Related Events (SREs)
Renal Impairment
Osteonecrosis of the Jaw (ONJ)
Bone involvement
Multiple Myeloma (MM)
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-02-13
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events (SREs) beyond 12 months treatment


Eligibility criteria: Inclusion criteria:

* Documented bone metastases from breast cancer, prostate cancer or multiple myeloma
* Prior treatment with zoledronic acid for 1-2 yrs
* Life expectancy of at least 6 months

Exclusion criteria:

* Prior treatment with bisphosphonates other than zoledronic acid
* Abnormal kidney function
* Current or previous dental problems or planned dental surgery
* Pregnant or likely to become pregnant during the study

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Safety assessed by incidence of renal impairment, osteonecrosis of the Jaw (ONJ), adverse events and serious adverse events. Efficacy assessed by incidence of skeletal related events (SREs).
timeFrame: 52 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Canberra
country: Australia
facility: Novartis Investigative Site
state: Australian Capital Territory
city: Concord
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Liverpool
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Wagga Wagga
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Redcliffe
country: Australia
facility: Novartis Investigative Site
state: Queensland
city: Townsville
country: Australia
facility: Novartis Investigative Site
state: Queensland
city: Woolloongabba
country: Australia
facility: Novartis Investigative Site
state: Queensland
city: Ballarat
country: Australia
facility: Novartis Investigative Site
state: Victoria
city: Box Hill
country: Australia
facility: Novartis Investigative Site
state: Victoria
city: Frankston
country: Australia
facility: Novartis Investigative Site
state: Victoria
Study officials:
affiliation: Novartis Pharmeceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT02592447: Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention
Official title: Preliminary Evaluation of an Internet-Assisted Cognitive Behavioral Intervention for Targeted Therapy Fatigue
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Myelogenous Leukemia
Keywords: CML
chronic phase CML
leukemia
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2015-10-30
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) with fatigued chronic myelogenous leukemia (CML) patients on tyrosine kinase inhibitors (TKIs) for feasibility, acceptability and potential efficacy relative to usual care only in a small-scale randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* able to speak/read English
* diagnosed with chronic phase CML
* not have been treated for other cancer (except non-melanoma skin cancer) in the past 5 years
* be under the care of a Moffitt Cancer Center (MCC) physician
* be on a stable dose of the same oral TKI for \>= 3 months
* new onset or worsening of fatigue since starting TKI
* report moderate-severe fatigue in past week (FSI average rating \>= 4 of 0-10)
* have no clinical history of disease (e.g., multiple sclerosis, fibromyalgia) that could account for their fatigue presentation

Exclusion Criteria:

* scheduled to discontinue their TKI under medical supervision within the next 3 months

Primary outcomes:
measure: Self-reported Fatigue Scores - Change From Baseline Per Scoring Category
timeFrame: Baseline and at 18 weeks
Secondary outcomes:
measure: Self-reported Quality of Life (QoL) Scores - Change From Baseline Per Scoring Category
timeFrame: Baseline and at 18 weeks
Other outcomes:
Locations:
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center and Research Institute
state: Florida
Study officials:
affiliation: H. Lee Moffitt Cancer Center and Research Institute
name: Heather Jim, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oswald LB, Hyland KA, Eisel SL, Hoogland AI, Knoop H, Nelson AM, Pinilla-Ibarz J, Sweet K, Jacobsen PB, Jim HSL. Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy. Support Care Cancer. 2022 Jan;30(1):87-94. doi: 10.1007/s00520-021-06408-1. Epub 2021 Jul 7.
Clinical trial NCT00711347: Intraoperative Floppy Iris Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Floppy Iris Syndrome
Keywords: Discovisc
Ophthalmic Visco Surgical Device
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2008-07-08
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: An assessment of the surgical performance of DisCoVisc compared to Healon5 during cataract surgery with intraocular lens implantation where miotic/small pupils or intraoperative Floppy Iris Syndrome exists.


Eligibility criteria: Inclusion Criteria:

* diagnosed with floppy iris syndrome
* operable bilateral cataracts

Exclusion Criteria:

* Intraocular Pressure (IOP) \> 21mmHg
* ocular inflammatory disease
* systemic or ocular diseases affecting Endothelial Cell Count

Primary outcomes:
measure: Corneal Endothelial Cell Loss
timeFrame: 1 month
Secondary outcomes:
measure: Intraocular Pressure (IOP)
timeFrame: 1 Day Postoperative
measure: Aqueous Signs - Cells
timeFrame: 1 Day Postoperative
measure: Aqueous Signs - Flare
timeFrame: 1 Day Postoperative
measure: Aqueous Signs - Edema
timeFrame: 1 Day Postoperative
measure: Surgeon Survey
timeFrame: Time of Surgery
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Contact Alcon Call Center for Study Locations
state: Texas
Study officials:
References:
Clinical trial NCT00534547: Duodenal Exclusion for the Treatment of Type 2 Diabetes
Official title: Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Diabetes
Lead sponsor: Medtronic - MITG
Sponsor class: INDUSTRY
First posted: 2007-09-26
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the role of an experimental surgery that may offer better short and long-term control of T2DM in select patients who have not achieved adequate blood sugar control with regular means.


Eligibility criteria: Inclusion criteria:

* Age between 20 and 50 years old;
* BMI between 27 and 34.9;
* Oral agents or insulin to control T2DM;
* Inadequate control of diabetes as defined as HbA1c\>8.0% but \<10%
* Understanding of the mechanisms of action of the treatment

Exclusion criteria:

* More than 5 years of T2DM diagnosis;
* C-peptide \<1pg/ml (off insulin)
* Previous abdominal operations;
* History of gastritis
* History of GERD
* History of peptic ulcer disease
* Inflammatory bowel disease
* Coagulopathy;
* Liver cirrhosis;
* Unable to comply with study requirements, follow-up schedule or give valid informed consent;
* Currently pregnant (pregnancy test required for confirmation for those of child bearing years)
* Patient is not available for programmed follow-up during the study period
* Patient is unwilling to forgo good samaritan blood donation during the study period

Primary outcomes:
measure: Treatment success based on patients' glycemic control
timeFrame: 12 Months
Secondary outcomes:
measure: Physiologic Measurements, Comorbidity improvement, Improvement in QOL
timeFrame: 12 Months
Other outcomes:
Locations:
Study officials:
affiliation: Medtronic - MITG
name: Noreen Fahey
role: STUDY_DIRECTOR
References: